Transparency Market Research states that the global mycoplasma diagnostics market will expand at a promising 10.6% CAGR over the period between 2016 and 2024, rising from a valuation of US$602.0 mn in 2016 to US$1.35 bn in 2024. The vast rise in the rate of prevalence of respiratory tract infections has emerged as the key growth driver for the global mycoplasma diagnostics market in the past few years. A report by the Forum of International Respiratory Society, published in 2013-2014, has predicted that deaths resulting from pulmonary conditions such as lung cancer, obstructive pulmonary diseases, and tuberculosis will rise at a worrisome pace in the next few years. The situation thus calls for effective methods of diagnosing these conditions so as to detect the diseases in their early stages.

Browse Report Details@ https://www.transparencymarketresearch.com/mycoplasma-diagnostics-market.html

Regionally, North America, Asia Pacific, Europe, Latin America, and the Middle East and Africa constitute the key market segments. Among these regions, North America held dominance in 2016 with an estimated share of 35.4% in the overall market. Several large research laboratories are present in North America. Besides this, the region also boasts a high level of public awareness, which provides an environment conducive to the growth of the mycoplasma diagnostics market. Furthermore, in the coming years, the market is expected to gain from the increasing demand for point of care testing. Despite dominance exercised by the North America market, during the forecast period Asia Pacific will showcase more lucrative opportunities. Besides the high incidence of respiratory tract infection witnessed in the last few years, the emerging nations in the region boasts high healthcare spending, which has helped the mycoplasma market exhibit strong growth in Asia Pacific. In addition, the regional market is forecast to gain from the rising demand for personalized medicines, rise in research and development investments, and the rising public awareness.

The global market for mycoplasma disorder featured the top five vendors, namely Thermo Fisher Scientific, Inc., F. Hoffmann-La Roche, Merck KGaA, Agilent Technologies, and Lonza Group accounting for over 68% of the overall market in 2016, observes Transparency Market Research (TMR) in a recent report. The high level of consolidation has ensued intense competition and increased focus of leading vendors on mergers and acquisitions, geographical expansion, and introduction of technologically advanced product varieties. With rise in mergers, acquisitions, and strategic collaborations, the market is expected to become less competitive in the next few years.

Report Overview, with TOC – https://www.transparencymarketresearch.com/report-toc/1677

US Office Contact

90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: [email protected]
Website: http://www.transparencymarketresearch.com/